• ryanjamesjessup

Inflammation Imaging Consulting

Updated: Apr 28

Imaging tissue inflammation normally employs CT and MRI technology and provides information regarding changes in the tissue. Molecular imaging is now adding to this imaging armamentarium by targeting specific inflammatory markers. Inflammatory processes continue to be recognized as key mechanisms in the pathogenesis of many diseases, including cardiovascular, obesity, arthritis, CNS and diabetes.

BioMolecular Imaging has experience serving on project committees for the development of inflammatory rheumatoid arthritis imaging in drug development.

Most specifically, working with DiaKine Therapeutics, we served in a key role during the development of IL-12 and STAT-4 inhibiting drugs for protection of islet cells.

Our knowledge of inflammatory pathways can be leveraged to assist your company in the development of new inflammation imaging agents or in the selection of currently available agents, including those for the TSPO receptor.

For more information please read a peer-reviewed publication from the Founder of BioMolecular Imaging, Dr. J. James Frost: "Brain Amyloid and Inflammation Imaging: A Convergence of Concepts"

About BioMolecular Imaging

BioMolecular Imaging (BMI Consultants) is a molecular imaging and clinical trial consultancy owned and operated by Dr. J. James Frost M.D./Ph.D out of Baltimore Maryland. BMI has been involved with clinical, therapeutic & diagnostic imaging focused on Oncology, Brain, Biomarkers, Cardiology and Central Image Interpretations for over 20 years.

To learn more about BioMolecular Imaging, please visit or connect with:

SoundCloud -

Facebook -

Twitter -

LinkedIn -

YouTube -

Copyright © 2022 BioMolecular Imaging

BioMolecular Imaging is a registered trademark of BioMolecular Imaging D.B.A. BMI Consultants

18 views0 comments

Recent Posts

See All

Diagnostic imaging is a core competency of BioMolecular Imaging - and is the approach of imaging the human body to analyze and form medical intervention, especially when viewing the function of organs

Imaging in therapeutic trials is the key process in expanding the understanding, methodology and metrics which are required to make determinations in drug targeting and efficacy. This spans most all i

A very active area of current investigation and commercialization is molecular and functional biomarker development. These biomarkers can serve as surrogate endpoints for therapeutic efficacy and are